A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20+ Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.
Year: 2009
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: University of Rochester Medicine, University of Rochester, University of Nebraska Medical Center, University of Wisconsin–Madison, Rocky Mountain Cancer Centers, Hackensack University Medical Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Genentech, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2980040380